Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomized, controlled, open‐label, crossover trial. Issue 2 (2nd November 2021)

• Record Type: Journal Article
• Authors: Pedersen‐Bjergaard, Ulrik; Agesen, Rikke M.; Brøsen, Julie M. B.; Alibegovic, Amra C.; Andersen, Henrik U.; Beck‐Nielsen, Henning; Gustenhoff, Peter; Hansen, Troels K.; Hedetoft, Christoffer; Jensen, Tonny J.; Juhl, Claus B.; Jensen, Andreas K.; Lerche, Susanne S.; Nørgaard, Kirsten; Parving, Hans‐Henrik; Sørensen, Anne L.; Tarnow, Lise; Thorsteinsson, Birger
• Is Part Of: Diabetes, obesity & metabolism. Volume 24:Issue 2(2022)
• Page Start: 257
• Page End: 267
• Publication Date: 2021-11-02
• Subjects: basal insulin -- hypoglycaemia -- insulin analogues -- phase IV study -- randomized trial -- type 1 diabetes; Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.14574
• Languages: English
• ISSNs: 1462-8902

Abstract

Abstract: Aim: To investigate whether the long‐acting insulin analogue insulin degludec compared with insulin glargine U100 reduces the risk of nocturnal symptomatic hypoglycaemia in patients with type 1 diabetes (T1D). Methods: Adults with T1D and at least one episode of nocturnal severe hypoglycaemia during the last 2 years were included in a 2‐year prospective, randomized, open, multicentre, crossover trial. A total of 149 patients were randomized 1:1 to basal‐bolus therapy with insulin degludec and insulin aspart or insulin glargine U100 and insulin aspart. Each treatment period lasted 1 year and consisted of 3 months of run‐in or crossover followed by 9 months of maintenance. The primary endpoint was the number of blindly adjudicated nocturnal symptomatic hypoglycaemic episodes. Secondary endpoints included the occurrence of severe hypoglycaemia. We analysed all endpoints by intention‐to‐treat. Results: Treatment with insulin degludec resulted in a 28% (95% CI: 9%‐43%; P = .02) relative rate reduction (RRR) of nocturnal symptomatic hypoglycaemia at level 1 (≤3.9 mmol/L), a 37% (95% CI: 16%‐53%; P = .002) RRR at level 2 (≤3.0 mmol/L), and a 35% (95% CI: 1%‐58%; P = .04) RRR in all‐day severe hypoglycaemia compared with insulin glargine U100. Conclusions: Patients with T1D prone to nocturnal severe hypoglycaemia have lower rates of nocturnal symptomatic hypoglycaemia and all‐day severe hypoglycaemia with insulin degludec compared with insulin glargine U100.